Ngā hua rapu kaituhi

1

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays mā Kathy S. Albain, Soonmyung Paik, Laura van’t Veer

I whakaputaina 2009

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
2

The MINDACT trial: The first prospective clinical validation of a genomic tool mā Fátima Cardoso, Martine Piccart, Laura Van't Veer, Emiel J. Rutgers

I whakaputaina 2007

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary mā John Bridgewater, Ryan K. van Laar, Arno Floore, Laura van’t Veer

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity mā Denise M. Wolf, Marc E. Lenburg, Christina Yau, Aaron Boudreau, Laura van ‘t Veer

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma mā Patti Curl, Igor Vujic, Laura van ‘t Veer, Susana Ortiz‐Urda, James G. Kahn

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. mā Guus Hateboer, H. T. Marc Timmers, AK Rustgi, Marc Billaud, Laura van ‘t Veer, René Bernards

I whakaputaina 1993

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

E2F-5, a New E2F Family Member That Interacts with p130 In Vivo mā E. Marielle Hijmans, P. Mathijs Voorhoeve, Roderick L. Beijersbergen, Laura van ‘t Veer, René Bernards

I whakaputaina 1995

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability mā Josien C.C. Scheepens, Laura van ‘t Veer, Laura J. Esserman, Jeffrey Belkora, Rita A. Mukhtar

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
9

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance mā Pavel Stejskal, Hani Goodarzi, Josef Srovnal, Marián Hajdúch, Laura van ‘t Veer, Mark Jesus M. Magbanua

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
10

Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. mā Mark J. Alkema, Marieke Bronk, Els Verhoeven, Arie P. Otte, Laura van ‘t Veer, A Berns, Maarten van Lohuizen

I whakaputaina 1997

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature mā Michael Knauer, Fátima Cardoso, Jelle Wesseling, Philippe L. Bédard, Sabine C. Linn, Emiel J. Rutgers, Laura van ‘t Veer

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis mā Alexandra J. van den Broek, Marjanka K. Schmidt, Laura van ‘t Veer, Rob A.�E.�M. Tollenaar, Flora E. van Leeuwen

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
13

Comparison of prognostic gene expression signatures for breast cancer mā Benjamin Haibe‐Kains, Christine Desmedt, Fanny Piette, Marc Buyse, Fátima Cardoso, Laura van’t Veer, Martine Piccart, Gianluca Bontempi, Christos Sotiriou

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Expression profiling predicts outcome in breast cancer mā Laura van ‘t Veer, Hongyue Dai, Marc J. van de Vijver, Yudong D. He, Augustinus A. M. Hart, René Bernards, Stephen Friend

I whakaputaina 2002

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Carta

Tiaki ki tētahi rārangi

I tiakina i:
15

Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer mā Rob Michalides, Alexander Griekspoor, Astrid Balkenende, Desirée Verwoerd, Lennert Janssen, Kees Jalink, Arno Floore, Arno Velds, Laura van 't Veer, Jacques Neefjes

I whakaputaina 2004

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

N-ras mutations in human cutaneous melanoma from sun-exposed body sites. mā Laura van ‘t Veer, Boudewijn Burgering, Rogier Versteeg, A J Boot, D. J. Ruiter, Susanne Osanto, Peter I. Schrier, Johannes L. Bos

I whakaputaina 1989

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

A protocol for building and evaluating predictors of disease state based on microarray data mā Lodewyk F.A. Wessels, Marcel J. T. Reinders, A.A.M. Hart, Cor J. Veenman, H. Dai, Yudong D. He, Laura van ‘t Veer

I whakaputaina 2005

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients mā James M. Ford, Sophie Adams, Taylor Sittler, Jeroen van den Akker, Salina Chan, Ofri Leitner, Lauren Ryan, Elad Gil, Laura van ’t Veer

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

A combined oncogenic pathway signature ofBRAF,KRASandPI3KCAmutation improves colorectal cancer classification and cetuximab treatment prediction mā Sun Tian, Iris Simón, Vı́ctor Moreno, Paul Roepman, Josep Tabernero, Mireille H.J. Snel, Laura van’t Veer, Ramón Salazar, René Bernards, Gabriel Capellà

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4–9 positive lymph nodes mā Mahasti Saghatchian, Stella Mook, Giancarlo Pruneri, Giuseppe Viale, Annuska M. Glas, Sylvie Guérin, Fátima Cardoso, Martine Piccart, Thomas Tursz, Suzette Delaloge, Laura van’t Veer

I whakaputaina 2013

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Laura Van't Veer

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays mā Kathy S. Albain, Soonmyung Paik, Laura van’t Veer

The MINDACT trial: The first prospective clinical validation of a genomic tool mā Fátima Cardoso, Martine Piccart, Laura Van't Veer, Emiel J. Rutgers

Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary mā John Bridgewater, Ryan K. van Laar, Arno Floore, Laura van’t Veer

Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity mā Denise M. Wolf, Marc E. Lenburg, Christina Yau, Aaron Boudreau, Laura van ‘t Veer

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma mā Patti Curl, Igor Vujic, Laura van ‘t Veer, Susana Ortiz‐Urda, James G. Kahn

TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. mā Guus Hateboer, H. T. Marc Timmers, AK Rustgi, Marc Billaud, Laura van ‘t Veer, René Bernards

E2F-5, a New E2F Family Member That Interacts with p130 In Vivo mā E. Marielle Hijmans, P. Mathijs Voorhoeve, Roderick L. Beijersbergen, Laura van ‘t Veer, René Bernards

Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability mā Josien C.C. Scheepens, Laura van ‘t Veer, Laura J. Esserman, Jeffrey Belkora, Rita A. Mukhtar

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance mā Pavel Stejskal, Hani Goodarzi, Josef Srovnal, Marián Hajdúch, Laura van ‘t Veer, Mark Jesus M. Magbanua

Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. mā Mark J. Alkema, Marieke Bronk, Els Verhoeven, Arie P. Otte, Laura van ‘t Veer, A Berns, Maarten van Lohuizen

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature mā Michael Knauer, Fátima Cardoso, Jelle Wesseling, Philippe L. Bédard, Sabine C. Linn, Emiel J. Rutgers, Laura van ‘t Veer

Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis mā Alexandra J. van den Broek, Marjanka K. Schmidt, Laura van ‘t Veer, Rob A.�E.�M. Tollenaar, Flora E. van Leeuwen

Comparison of prognostic gene expression signatures for breast cancer mā Benjamin Haibe‐Kains, Christine Desmedt, Fanny Piette, Marc Buyse, Fátima Cardoso, Laura van’t Veer, Martine Piccart, Gianluca Bontempi, Christos Sotiriou

Expression profiling predicts outcome in breast cancer mā Laura van ‘t Veer, Hongyue Dai, Marc J. van de Vijver, Yudong D. He, Augustinus A. M. Hart, René Bernards, Stephen Friend

Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer mā Rob Michalides, Alexander Griekspoor, Astrid Balkenende, Desirée Verwoerd, Lennert Janssen, Kees Jalink, Arno Floore, Arno Velds, Laura van 't Veer, Jacques Neefjes

N-ras mutations in human cutaneous melanoma from sun-exposed body sites. mā Laura van ‘t Veer, Boudewijn Burgering, Rogier Versteeg, A J Boot, D. J. Ruiter, Susanne Osanto, Peter I. Schrier, Johannes L. Bos

A protocol for building and evaluating predictors of disease state based on microarray data mā Lodewyk F.A. Wessels, Marcel J. T. Reinders, A.A.M. Hart, Cor J. Veenman, H. Dai, Yudong D. He, Laura van ‘t Veer

Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients mā James M. Ford, Sophie Adams, Taylor Sittler, Jeroen van den Akker, Salina Chan, Ofri Leitner, Lauren Ryan, Elad Gil, Laura van ’t Veer

Ngā utauta rapu:

Ngā marau whai pānga